This Popular Produce Item is Being Recalled Nationwide for a Serious Problem—Here's What You Need to Know
Nobody wants to hear that their favorite grocery items have been flagged for recall. Despite the inconvenience, recalls are a necessary process in our modern world of mass-production. Issues like mislabeled products, unknown contaminants and faulty packaging unfortunately slip through the cracks all the time.
This week, Ray & Mascari Inc. of Indianapolis, Indiana, is recalling its 4-count Vine Ripe Tomatoes due to a potential contamination with Salmonella. The tomatoes were packaged in 20-ounce clamshell containers and sold by Gordon Food Service Stores in Illinois, Indiana, Kentucky, Michigan, Missouri, Mississippi, New York, Ohio, Pennsylvania, Tennessee and Wisconsin.
😋😋🍳🍔For those unaware, Salmonella is an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people and other switch weakened immune systems. Healthy individuals can experience fever, diarrhea, nausea, vomiting and abdominal pain. In super rare circumstances, Salmonella infection can even result in arterial infections, endocarditis and arthritis.
According to the FDA announcement, Ray & Mascari Inc. was informed of the tomato recall by Hanshaw & Capling Farms of Immokalee, Florida, who received and repackaged the 4-Count Vine Ripe Tomatoes and then initiated the recall due to the potential presence of Salmonella in their facility. The recalled product features UPC #7 96553 20062 1, and has a master case label with Lot# RM250424 15250B or Lot# RM250427 15250B.
While no illnesses have been reported to date in relation to the recall, consumers are urged not to consume the product and rather discard it altogether. Those with further questions or reports of illness can contact Ray & Mascari Inc. at 1-317-637-0234, Monday - Saturday, 6am - 5pm EST.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Breakthrough procedure helps prevent amputations for Sacramento area patients
( — A breakthrough surgery helping save limbs and lives took place in Sacramento on Wednesday morning. The procedure aims to treat people suffering from Peripheral Artery Disease. PAD is a serious and rarely-treated circulatory condition that restricts blood flow to the limbs due to narrowed blood vessels. It kills more people than breast, colon, and prostate cancer combined. 'Plaque that builds up in these arteries causes not only hardening of the arteries but also plaque in these blood vessels,' said Dr. Inder Singh, an interventional cardiovascular specialist at TLC Vascular. When blood can't flow properly, minor wounds can become dangerous. They can lead to infection and, in some cases, amputation. Michaels Distributing Center in San Joaquin County set to close, affecting over 200 jobs 'If they get an injury or they get a wound or they get a scratch, those will not heal because they don't have enough, adequate perfusion to heal those wounds,' Dr. Singh said. Helping to change patient outcomes, Dr. Singh is now performing a first-of-its-kind procedure using a newly FDA-cleared removable stent called SPUR. 'The idea with it is that basically that kind of treatment that deep penetrates into the tissue and treats it, it will prevent future closure or at least prolong the time from when the blood vessels close,' said Dr. Singh. 'Enabling the patients to be able to heal their wounds, which is really the main outcome we're looking for.' is the first in the Sacramento area to use SPUR, designed specifically for the small, fragile arteries below the knee. Unlike a traditional stent, the spur temporarily holds the vessel open and then is removed, leaving nothing behind. Charges filed against former Cal Fire employee in child pornography case 'We can see somebody on an outpatient basis one day and actually fix a problem rather than put a band-aid on, you know, the incorrect problem,' said Shelby Adney, a nurse practitioner at TLC Vascular. It's an innovative procedure now preventing amputations, healing wounds, and maintaining patients' normal lives. 'Once you can preserve that and heal their wounds… they get their life back,' Dr. Singh said. 'They're ambulatory. They can spend time with their family. You can do a lot of things that most people expect to do.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
7 hours ago
- Yahoo
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD). In the first week of June, Mesoblast held a Type B meeting with FDA under its Regenerative Medicines Advanced Therapy (RMAT) designation for REVASCOR to discuss components of a potential filing for a Biologics License Application (BLA). There was general alignment on items regarding chemistry, manufacturing & controls (CMC), potency assays for commercial product release, and proposed design and primary endpoint for the confirmatory trial post-approval. The Company will await the final minutes from FDA in order to provide detailed feedback and timelines for potential filing. In early July, Mesoblast has an upcoming meeting with FDA to discuss a pivotal trial of Ryoncil® in adults with SR-aGvHD. This trial will be conducted with the NIH-funded Bone Marrow Transplant Clinical Trials Network (BMT-CTN), the objective being to extend the product's label from children to adults with SR-aGvHD. Ryoncil® is the first and only mesenchymal stromal cell product approved by the FDA for any indication. Ryoncil® became commercially available for purchase in the United States on March 28, 2025, within one quarter of receiving FDA approval to treat children with SR-aGvHD. More than 20 transplant centers will have been onboarded by the end of the quarter, exceeding the company's expectations at product launch. Mesoblast has continued to expand coverage for Ryoncil® to over 220 million US lives insured by commercial and government payers. To date, 37 of the 51 States provide fee-for-service Medicaid coverage for Ryoncil® through Orphan Drug Lists or medical exception / prior authorization (PA) process. The remainder will come online July 1, 2025, with mandatory coverage for all 24 million lives. 'We are very pleased with the momentum of interactions with FDA on both our cardiac and GvHD programs,' said Mesoblast Chief Executive Dr. Silviu Itescu. 'We are also encouraged by the strength of the of the Ryoncil® commercial launch, the rate of hospital onboarding, physician adoption, and payor coverage exceeding our expectations in the ten weeks since commercial launch. We will be providing an update on sales of Ryoncil® in our quarterly activities report at the end of next month.' About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast's RYONCIL® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. RYONCIL is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets. About Mesoblast manufacturing: The Company's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see LinkedIn: Mesoblast Limited and X: @Mesoblast Forward-Looking StatementsThis press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast's preclinical and clinical studies, and Mesoblast's research and development programs; Mesoblast's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast's ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast's RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast's product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast's ability to enter into and maintain established strategic collaborations; Mesoblast's ability to establish and maintain intellectual property on its product candidates and Mesoblast's ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast's expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast's financial performance; developments relating to Mesoblast's competitors and industry; and the pricing and reimbursement of Mesoblast's product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Release authorized by the Chief Executive. For more information, please contact:Paul Hughes T: +61 3 9639 6036 Allison Worldwide Emma Neal T: +1 603 545 4843 E: BlueDot Media Steve Dabkowski T: +61 419 880 486 E: steve@
Yahoo
8 hours ago
- Yahoo
SNHD identifies 4 cases of salmonella in Clark County linked to multi-state outbreak
LAS VEGAS (KLAS) — The Southern Nevada Health District identified several cases of salmonella in Clark County in connection to a multi-state outbreak linked to brown eggs. The SNHD identified four cases of salmonella in Clark County as of Wednesday as the Centers for Disease Control and Prevention (CDC) leads a coordinated investigation into the outbreak linked to brown cage-free and brown-certified organic eggs. As of Wednesday, at least 50 salmonella-related illnesses have been reported nationwide. Salmonella can cause serious illness and symptoms typically begin six hours to six days after exposure. Symptoms include diarrhea, fever and stomach cramps. Salmonella outbreak tied to eggs sickens dozens across 7 states SNHD said most people recover without medical treatment, but some, especially young children, older adults, and people with weakened immune systems are at greater risk of developing severe illnesses or complications that may require hospitalization. The CDC is advised the following: Do not eat any recalled eggs. Throw them away or return them to where you bought them. Wash items and surfaces that may have touched the recalled eggs using hot soapy water or a dishwasher. Call your health care provider if you have any of these severe Salmonella symptoms: Diarrhea or vomiting lasting more than two days A fever higher than 102°F Bloody diarrhea or bloody urine So much vomiting that you cannot keep liquids down Signs of dehydration, such as not peeing much, dry mouth and throat, and feeling dizzy when standing up For more information about the outbreak, including safety tips and product recall details, is available on the CDC's website or on the U.S. Food and Drug Administration website. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
